Judge Denies FDA Bid to Stay 'Morning-after' Pill Ruling

A federal judge in New York on Friday declined to temporarily halt a court order directing the U.S. Food and Drug Administration to make emergency contraception available over the counter to girls of all ages.

However, U.S. District Judge Edward Korman in Brooklyn said he would give the FDA until May 13 to ask a federal appeals court in Manhattan to stay the order, which had been scheduled to take effect on Friday.

Korman ordered the FDA on April 5 to lift age and point-of-access restrictions on all levonorgestrel-based emergency contraception, also known as the "morning-after" pill or "Plan B," to prevent unwanted pregnancies. The FDA has appealed that ruling.

"In my view, the defendants' appeal is frivolous and taken for the purposes of delay," Korman wrote in Friday's decision.

The case stems from a 2005 lawsuit filed by a coalition of reproductive rights advocates who sought to lift age and access restrictions on emergency contraception.

At the time of Korman's original April ruling, emergency contraception was available without a prescription to women 17 years and older who presented identification at a pharmacist's counter.

Late last month, the FDA said it would allow girls as young as 15 to buy a one-pill version of emergency contraception, Plan B One-Step, made by a unit of Teva Pharmaceutical Industries without a prescription.

The agency said its decision was unrelated to the court ruling and based on data from Teva showing teens that age could take the drug safely.

In the April 5 ruling, Korman called the agency's restrictions on emergency contraception "arbitrary, capricious and unreasonable," and gave it 30 days to make the drug available over the counter to women of all ages.

If taken up to 120 hours after unprotected sex, emergency contraception is designed to prevent pregnancy.

FDA and Teva officials declined to comment.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences

The Start-up Platform for Chemistry & Life Sciences

The tasks range from employee protection, site security and crisis management to IT, OT and production security.

Interview

Innovation at the Intersection of AI
Digital Potential in Key Business Areas

Innovation at the Intersection of AI

Stefan Guertzgen spoke with John Banovetz, Chief Technology Officer at 3M, about the role of digital transformation in achieving the company's objectives.

most read

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.